Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BeOne Medicines Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BeOne Medicines Ltd.'s regulatory disclosures and financial reporting.
Chan Lee has filed to sell shares of BeOne Medicines under Rule 144. The planned transaction covers 718,718 American Depositary Shares (ADS), acquired in 2002, to be sold through Morgan Stanley Smith Barney LLC – Executive Financial Services on the NASDAQ, with a listed event date of 08/11/2026. The filing also notes that the ADS to be sold relate to the exercise of stock options for cash.
Over the prior three months, Lee reported multiple open-market sales, including 1,044 common shares for $337,932.36 on 07/30/2026 and several ADS transactions such as 1,669 ADS for $542,425.00 on 07/22/2026, 664 ADS for $200,833.44 on 07/08/2026, and additional ADS sales in June and May 2026, some under a Rule 10b5-1 trading plan.
The filing by insiders of ONC details planned and recent sales of equity under Rule 144. It lists 240,810 ADS to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $83,866,898.70, for trading on NASDAQ on or after August 10, 2026. The securities to be sold include ADS obtained from previously exercised stock options and ADS from founders shares. The filing also reports multiple recent 10b5-1 sales of ADS and common shares by John V. Oyler and the Pan-Oyler Foundation over June and July 2026, providing dates, share amounts, and dollar values for each transaction.
BeOne Medicines Ltd. Chief Financial Officer Aaron Rosenberg sold 1,157 American Depositary Shares at $312.715 per ADS on August 3, 2026, to satisfy mandatory tax withholding tied to vesting of a restricted share unit award. After this transaction he held 382,850 Ordinary Shares directly. Each American Depositary Share represents 13 Ordinary Shares, and the restricted share unit award vests in four equal annual installments on each anniversary of July 31, 2024, with remaining unvested units eligible for accelerated vesting upon certain termination events.
BeOne Medicines Ltd. reported strong results for the quarter ended June 30, 2026, with total revenues of $1,705,071 (amounts in thousands of $), up 29.6% from $1,315,300 a year earlier. Net income rose to $237,007 from $94,320, and diluted earnings per share were $0.16, or $2.05 per ADS.
Growth was driven mainly by oncology portfolio expansion: BRUKINSA® net product revenue increased 31.4% to $1,247,640, TEVIMBRA® grew 18.1% to $228,515, and Amgen‑in‑licensed products such as XGEVA® and BLINCYTO® also posted double‑digit gains. Overall net product revenue rose 29.0% to $1,679,794, while other revenue nearly doubled to $25,277.
Gross profit improved to $1,530,541, reflecting an 89.6% product gross margin. Research and development expense grew 16.6% to $612,280 and selling, general and administrative expense rose 10.3% to $593,214 as the company invested in its pipeline and global commercialization. Cash and cash equivalents were $5,098,041 at June 30, 2026, alongside $882,163 of long‑term debt, $190,896 of short‑term debt, and a $906,313 sale‑of‑future‑royalty liability.
BeOne Medicines reported strong Q2 2026 results, with total revenue of $1,705,071 thousand, up 30% year over year. Net product revenue was $1,679,794 thousand, driven by BRUKINSA global sales of $1.2 billion (31% growth), TEVIMBRA sales of $229 million (18% growth), and Amgen in-licensed products at $157 million (25% growth). GAAP income from operations rose to $325,047 thousand, GAAP net income to $237,007 thousand, and GAAP diluted EPS per ADS to $2.05, while adjusted diluted EPS per ADS reached $3.84. Gross margin improved to 90% from 87%, and Free Cash Flow increased to $435,344 thousand. Cash, cash equivalents and restricted cash were $5,280,674 thousand as of June 30, 2026.
Management raised 2026 guidance, now expecting total revenue of $6.6–$6.8 billion, GAAP operating income of $1.0–$1.1 billion, and non-GAAP operating income of $1.7–$1.8 billion. Updates included positive BRUKINSA Phase 3 data, FDA accelerated approval for BEQALZI in relapsed/refractory mantle cell lymphoma, Japan approval for TEVIMBRA in first-line gastric cancer, U.S. FDA Orphan Drug Designation for PRMT5 inhibitor BGB-58067, and a $300 million expansion of the Princeton West manufacturing and R&D campus.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry reported a sale of 1,044 American Depositary Shares on July 30, 2026 at $323.69 per ADS. The sale was executed under a mandatory tax-withholding provision tied to vesting of a restricted share unit award. Each ADS represents 13 ordinary shares, and following the transaction he directly holds 325,312 ordinary shares. The RSU award vests 1/4 of the securities on each anniversary of July 29, 2022, subject to continued service.
ONC affiliate Aaron Rosenberg filed to potentially sell up to 1,157 American Depositary Shares (ADS) on NASDAQ through Morgan Stanley Smith Barney LLC’s Executive Financial Services. The ADS relate to restricted stock vesting under a registered plan scheduled on July 31, 2026.
The filing also lists a prior transaction during the past three months, where 631 ADS were sold on June 11, 2026 for an aggregate amount of $162,636.53.
Chan Lee, an affiliate of ONC, has filed to sell up to 1,044 American Depositary Shares (ADS) through Morgan Stanley Smith Barney LLC Executive Financial Services on or after July 30, 2026 on NASDAQ, with an indicated aggregate market value of $337,932.36. These ADS were acquired via restricted stock vesting under a registered plan on July 29, 2026. Over the prior three months, Chan Lee has sold multiple ADS blocks, including 1,669 ADS for $542,425.00 on July 22, 2026 and 644 ADS for $200,833.44 on July 8, 2026.
BeOne Medicines Ltd. SVP and general counsel Lee Chan Henry exercised options for 21,697 ordinary shares on July 22, 2026, at exercise prices of $14.96, $16.41 and $12.23 per share. He acquired American Depositary Shares at prices of $194.47, $213.32 and $159.03 per ADS, and sold 1,669 ADS at $325 pursuant to a Rule 10b5-1 trading plan adopted on May 29, 2026. After these transactions he held 338,884 ordinary shares directly.
BeOne Medicines Ltd. director and Chief Executive Officer John Oyler exercised share options covering 441,870 Ordinary Shares at an exercise price of $9.23 per share and on the same date acquired 33,990 American Depositary Shares through an exercise or conversion transaction at $119.96 per ADS.
On July 20–21, 2026, he sold an aggregate 109,713 American Depositary Shares in multiple open-market or private transactions at weighted-average prices within ranges from $309.39 to $320.39 per ADS under a Rule 10b5-1 trading plan adopted on March 10, 2026. After these trades he reported 4,461,518 Ordinary Shares held directly, plus additional Ordinary Shares held indirectly through various trusts and entities, some of which he disclaims beneficial ownership. Each American Depositary Share represents 13 Ordinary Shares.